Showing 3831-3840 of 5646 results for "".
- Ocuphire Pharma Names Joseph Schachle as COOhttps://modernod.com/news/ocuphire-pharma-names-joseph-schachle-as-coo/2481981/Ocuphire Pharma announced the appointment of Joseph (Joe) K. Schachle, MBA, into the newly created role of Chief Operating Officer, effective immediately. Ocuphire is a clinical-stage company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refra
- Emily Chew, MD, Named NIH Distinguished Investigatorhttps://modernod.com/news/emily-chew-md-named-nih-distinguished-investigator/2481980/Emily, Chew, MD, has been promoted to the title of NIH Distinguished Investigator for her work as a care provider and clinical trialist. Dr. Chew directs National Eye Institute's Division of Epidemiology and Clinical Applications (DECA). An ophthalmologist, she specializes in c
- Pixium Vision Receives Takeover Offerhttps://modernod.com/news/pixium-vision-receives-takeover-offer/2481976/Pixium Vision, whose safeguard proceedings were converted into receivership by the Paris Commercial Court on November 13, 2023, announced that the court-appointed administrators have received a takeover offer for the assets and activities of Pixium. The name of the a
- Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMDhttps://modernod.com/news/inflammasome-therapeutics-to-enter-clinic-with-treatment-for-dry-amd/2481974/Inflammasome Therapeutics, developer of a new class of inflammasome inhibitor drugs called Kamuvudines, announced the FDA has granted approval for the opening of a phase 1/2 clinical trial of the company’s drug for the treatment of geographic atrophy (GA). This is the first clinical tr
- Injectsense and Injectpower Secure $9.4M to Support Injectsense's First-in-Human Studies for Sensors that Continuously Measure IOPhttps://modernod.com/news/injectsense-and-injectpower-secure-94m-to-support-injectsenses-first-in-human-studies-for-sensors-that-continuously-measure-iop/2481973/Injectsense and sister company Injectpower, a developer of ultra-miniature solid-state microbatteries for medical applications, announced combined funding of $9.4 million to bring highly integrated autonomous implantable devices—smaller than a grai
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- Regenxbio Presents New Data on Investigational AAV Therapeutic for Retinal Conditionshttps://modernod.com/news/regenxbio-presents-new-data-on-investigational-aav-therapeutic-at-aao/2481967/At the American Academy of Ophthalmology 2023 Annual Meeting in San Francisco, new data was presented for Regenxbio's ABBV-RGX-314, an investigational one-time AAV therapeutic being developed in collaboration with AbbVie for the treatment of wet age-related macular degener
- Orcam Technologies Unveils Orcam Read 3 AI-Driven Solution for People with Low Vision and Visual Impairmentshttps://modernod.com/news/orcam-technologies-unveils-orcam-read-3-ai-driven-solution-for-people-with-low-vision-and-visual-impairments/2481965/OrCam Technologies has introduced the OrCam Read 3, which is designed to improve the way people with vision loss and reading difficulties interact with visual materials. User point the device at a book, computer screen, product packaging or any text, and the AI technology will loudly and cle
- First Patient Dosed in Ocugen's Phase 1/2 Trial Evaluating Safety and Efficacy of OCU41OST Modifier Gene Therapy for Stargardt Diseasehttps://modernod.com/news/first-patient-dosed-in-ocugens-phase-12-trial-evaluating-safety-and-efficacy-of-ocu41ost-modifier-gene-therapy-for-stargardt-disease/2481960/Ocugen announced that the first patient has been dosed in its phase 1/2 GARDian clinical trial for OCU410ST (AAV5-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease. “There is a significant unmet medical need for the approximate 35,000 patien
- Visionix Announces Strategic Partnership with 20/20NOWhttps://modernod.com/news/visionix-announces-strategic-partnership-with-2020now/2481957/Visionix USA announced it has entered a into a strategic alliance with 20/20NOW with the aim of bringing cost-effective, in-office, synchronous tele-optometry eye exams and ocular telemedicine closer to more patients throughout the United States. Financial terms of the deal we